Figure 1.

Progression-free survival and overall survival in the total population (A, C) and in a subgroup of patients with blastoid and pleomorphic disease (B, D). A total of 59 out of 124 patients died (47.6%); causes include disease progression (N=40), adverse event (N=6 [1 patient experienced treatment-related myelodysplastic syndrome and died from pneumonia]), other cause (N=6), or unknown cause (N=7). Deaths due to “other cause” include secondary acute myeloid leukemia (N=2), lung cancer (N=1), pneumonia (N=1), intestinal obstruction (N=1), and graft-versus-host disease (N=1). Deaths due to “unknown cause” include a patient who died at home (N=1) and who had been qualified to next line of therapy (N=1). PFS: progression-free survival; CI: confidence interval; NE: not estimable; OS: overall survival.